Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Aquacel Ag Gelled, Aquacel Ag Adherent · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Gelled | ACTIVE_COMPARATOR | Aquacel Ag gelled. |
| Adherent | ACTIVE_COMPARATOR | Aquacel Ag adherent |
| Name | Type | Description |
|---|---|---|
| Aquacel Ag Gelled | DEVICE | AQUACEL Ag is produced by changing a small fraction of the sodium ions present in AQUACEL for silver ions and then stabilizing the complex formed by adding chloride. This produces a characteristic silver gray product. There are no counter ions (such as nitrate or sulphadiazine ions) present: these compounds, found in many silver containing products, are known to retard wound healing. AQUACEL Ag maintains a moist wound-healing environment while, at the same time, killing wound pathogens that are immobilized within the dressing. It also reduces bioburden at the wound-dressing surface, thus minimizing the risk of wound infection and facilitating wound healing. |
| Aquacel Ag Adherent | DEVICE | AQUACEL Ag is produced by changing a small fraction of the sodium ions present in AQUACEL for silver ions and then stabilizing the complex formed by adding chloride. This produces a characteristic silver gray product. There are no counter ions (such as nitrate or sulphadiazine ions) present: these compounds, found in many silver containing products, are known to retard wound healing. AQUACEL Ag maintains a moist wound-healing environment while, at the same time, killing wound pathogens that are immobilized within the dressing. It also reduces bioburden at the wound-dressing surface, thus minimizing the risk of wound infection and facilitating wound healing. |
Inclusion Criteria: * Subject or legally authorized representative must provide written informed consent. * Subject who is younger than legal consenting age must have a legally authorized representative who will provide written informed consent. * The subject is scheduled to undergo a split-thickne...
Aquacel Ag Gelled is used for the management of split-thickness donor sites, which are areas of skin harvested for grafting. It is a wound care product designed to be applied to these sites to support healing. The product is currently in Phase 3 clinical development for this indication.
Aquacel Ag Adherent is used for the management of split-thickness donor sites, which are areas of skin harvested for grafting. It is a wound care product designed to be applied to these sites to support healing. The product is currently in Phase 3 clinical development for this indication.
Aquacel Ag Gelled is developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. The company is conducting clinical trials to evaluate the product for the management of split-thickness donor sites.
Aquacel Ag Adherent is developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. The company is conducting clinical trials to evaluate the product for the management of split-thickness donor sites.
Aquacel Ag Gelled is in Phase 3 clinical development. It is being studied for the management of split-thickness donor sites. The product is investigational and has not been approved by regulatory authorities based on the available information.
Aquacel Ag Adherent is in Phase 3 clinical development. It is being studied for the management of split-thickness donor sites. The product is investigational and has not been approved by regulatory authorities based on the available information.